Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 5Phase 1/2 4Phase EARLY_PHASE1 1Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 6pembrolizumab 5Radiosurgery 5Nivolumab 4Fluorouracil 4Carboplatin 4Blood Specimen Collection 4Biopsy 4X-Rays 3Vincristine 3Surveys and Questionnaires 3Proflavine 3Positron-Emission Tomography 3Metformin 3Cisplatin 3Bevacizumab 3fludarabine phosphate 2durvalumab 2atezolizumab 2Varenicline 2Topotecan 2Taxes 2Specimen Handling 2Rituximab 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × copanlisib × Clear all
NCT04803123 2023-12-21

Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL

Duke University

Phase EARLY_PHASE1 Terminated
3 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡